Author pages are created from data sourced from our academic publisher partnerships and public sources.
The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines
Melanoma, the most deadly form of skin cancer, is aggressive and resistant to current therapies. It has been previously reported that the substance P and neurokinin-1 (NK-1) receptor antagonists… Expand
A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage
- F. Esteban, M. Munoz, M. Gonzalez-Moles, M. Rosso
- Biology, Medicine
- Cancer and Metastasis Reviews
- 1 March 2006
In the present review we discuss a central role for substance P (SP) in carcinogenesis. We suggest that one mechanism to induce mitogenesis of tumor cells is the activation of neurokinin-1 receptor… Expand
The NK-1 receptor: a new target in cancer therapy.
After binding to the specific neurokinin-1 (NK-1) receptor, the peptide substance P (SP), which is widely distributed in both the central and peripheral nervous systems, induces tumor cell… Expand
The NK-1 Receptor is Involved in the Antitumoural Action of L-733,060 and in the Mitogenic Action of Substance P on Human Pancreatic Cancer Cell Lines
The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug
SummaryAprepitant is a selective high-affinity antagonist of human substance P (SP)/Neurokinin-1 (NK-1) receptors. Until now this drug has been used as anxiolytic, antidepressant and antiemetic. It… Expand
The substance P/neurokinin-1 receptor system in lung cancer: Focus on the antitumor action of neurokinin-1 receptor antagonists
- Miguel Muñoz, A. González-Ortega, M. Rosso, M. Robles-Frías, R. Coveñas
- Biology, Medicine
- 1 December 2012
The last decades have seen no significant progress in extending the survival of lung cancer patients and there is an urgent need to improve current therapies. The substance P (SP)/neurokinin-1… Expand
Antitumoural action of L-733,060 on neuroblastoma and glioma cell lines.
- M. Muñoz, A. Pérez, R. Coveñas, M. Rosso, E. Castro
- Medicine, Psychology
- Archives italiennes de biologie
- 1 March 2004
We have performed an in vitro study of the growth-inhibitory capacity of the potent and long-acting NK1 receptor antagonist L-733,060, at concentrations ranging from 2.5 microM to 20 microM, against… Expand
The NK-1 Receptor Antagonist L-732,138 Induces Apoptosis and Counteracts Substance P-Related Mitogenesis in Human Melanoma Cell Lines
It has been recently demonstrated that substance P (SP) and neurokinin-1 (NK-1) receptor antagonists induce cell proliferation and cell inhibition in human melanoma cells, respectively. However, the… Expand
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
The past two decades have witnessed an exponential increase in research into cancer. This effort, however, has not been translated into better perspectives as regards the problem, although several… Expand
beta Interferon inhibits HIV-1 Tat-induced angiogenesis: synergism with 13-cis retinoic acid.
- Monica Iurlaro, R. Benelli, L. Masiello, M. Rosso, L. Santi, A. Albini
- European journal of cancer
- 1 March 1998
Kaposi's sarcoma (KS) is a highly angiogenic lesion which frequently presents as an aggressive form in HIV-infected male patients. We have previously shown that the HIV-1 Tat protein induces… Expand